Novartis ends BioArctic BrainTransporter collaboration, forfeiting up to $772 million in milestones
Novartis announced on 2 Nov 2026 that it is terminating its August 2025 option, collaboration and license agreement with BioArctic AB. The deal paired BioArctic’s BrainTransporter platform with an undisclosed Novartis antibody for a neurodegeneration program. BioArctic will keep the $30 million upfront payment and will recognize the remaining unearned portion as revenue in 2026. The termination is unrelated to the BrainTransporter technology and does not affect BioArctic’s other partnerships.
Why it matters
BioArctic’s shares fell more than 7% in early trading after the news, reflecting the loss of a potential $772 million milestone stream (the company said). The retained $30 million upfront payment and existing collaborations mitigate the impact, but future revenue from this partner is now gone.
Key facts
- 1Novartis announced the termination on 2 Nov 2026. biostock.se
- 2The original agreement was signed in August 2025. biostock.se
- 3BioArctic received a $30 million upfront payment, which it will retain. biostock.se
- 4Novartis forfeited up to $772 million in potential milestone payments. biostock.se
- 5BioArctic will recognize the remaining unrecognized portion of the upfront fee as revenue in 2026. biostock.se
- 6BioArctic reported SEK 1,990 million in cash and short‑term investments at the end of June. european-biotechnology.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.